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Radiation therapy (RT) technology and utilization has considerably
evolved over the last 50 years in the management of pediatric Hodgkin
lymphoma (HL). In response to significant late effects from RT in survi-
vors of HL, clinical trials in the United States and Europe have evaluated
ways to maintain high cure rates while reducing late toxicities from treat-
ment. Numerous differences exist with respect to the RT guidelines
embedded within therapeutic protocols across cooperative groups, but
greater agreement is observed in the indications for RT, doses, volumes,
and the incorporation of modern treatment modalities. This report provides
an overview of RT delivery in pediatric HL protocols in the United States
and Europe and examines areas of consensus on the utilization and deliv-
ery of RT in pediatric HL.
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Introduction
Radiation therapy (RT) has played a central role in the man-
agement of Hodgkin lymphoma (HL) for more than
50 years. Palliative RT was replaced with large fields deliv-
ered with curative treatment intent during the 1950s and
1960s.1 Over time, combined modality therapy (CMT) with
chemotherapy followed by consolidative RT has increased
cure rates while often using less intensive chemotherapy
regimens and smaller RT fields at lower doses. The 10-year
overall survival now exceeds 85% with CMT for pediatric
patients with HL. Efforts continue to improve cure rates in
the highest-risk patients, but the goal of contemporary HL
therapy is now largely focused on reducing the late adverse
effects of treatment using risk- and response-adapted thera-
pies without compromising outcomes.2,3
Substantial heterogeneity exists between national and
international clinical trial protocols for pediatric and adult
HL regarding optimal RT utilization. This contributes to dis-
parate recommendations regarding indications for RT, sites
requiring RT, field design, dose, permissible modalities, and
motion management strategies. The Staging, Evaluation, and
Response Criteria Harmonization for Childhood, Adolescent,
and Young Adult Hodgkin Lymphoma initiative was formed
in 2011 to promote collaboration among an international
group of pediatric HL investigators who actively participate
in cooperative group clinical trials. The aim of this team is to
develop a unified framework to approach staging, response
assessment, and treatment efficacy across pediatric HL clini-
cal trial groups to enhance the design and execution of clini-
cal trials. In this report, our purpose is to review and detail
critical aspects of RT delivery that should be considered by
pediatric, medical, and radiation oncologists interested in
developing future HL trials.
Should Radiation Therapy Be Given to All
Patients, Slow Early and Partial Responders to
Chemotherapy, Patients With Bulky Disease, or
None at All?
Historically, RT utilization was not a research question
because all children and adults received RT either alone or
combined with chemotherapy. Contemporary studies where
all patients received RT were generally limited to stage I/II
patients for whom the prechemotherapy extent of disease
could be encompassed within reasonable RT fields.4,5 Of
note, some trials from earlier eras included higher-risk
patients with stage III/IV disease who were treated with
much larger fields.6-9 In these trials, the study questions
generally focused on treatment intensity, but all patients
received combined modality therapy. For example, Hudson
et al compared the efficacy of lower doses of involved-field
RT (IFRT) of 15.5 Gy for patients with a complete response
(CR) after chemotherapy compared with 25.5 Gy after a
partial response (PR).7
The optimization of treatment intensity in HL necessi-
tates a standardized and reproducible method of assessing
treatment response. Definitions of response, however, vary
according to the timepoint(s) of evaluation and the ana-
tomic and metabolic criteria employed, and they diverge
across individual clinical trials and national and interna-
tional research consortia.10,11 Interim response has been
used to identify rapid early responders who may potentially
receive less intensive therapy without compromising out-
comes, whereas slow responders may benefit from treat-
ment intensification.6,12,13 Earlier studies employed
computed tomography (CT) for response assessment, but
over time, functional imaging has been increasingly used
(Gallium or fluorodeoxyglucose [FDG] positron emission
tomography [PET]).10 Some more recent studies have even
relied solely on metabolic response by functional imaging
to assess response (NCT03907488, NCT03755804).
Over time, more intensive chemotherapy regimens were
implemented to mitigate the need for large RT fields, partic-
ularly in patients with advanced disease. Successive trials
demonstrated the increasing effectiveness of chemotherapy
in improving relapse-free survival. Despite these advances,
however, selected patients still relapsed, and identification
of high-risk patients who may benefit from treatment inten-
sification is an important need. For example, patients with
bulky disease and less than CR were identified to have a
higher risk of relapse with chemotherapy alone in multiple
reports.12,14-16 Ongoing reevaluation of the value of using
RT in such high-risk patients, including those with bulky
disease, is warranted.
Several pediatric trials evaluated the benefit of RT in
patients with a CR to chemotherapy and included both ran-
domized and nonrandomized evaluations of omitting RT in
complete responders with early stage unfavorable,2,12,17
early stage favorable,2,9,12,13,18 and advanced
disease.2,6,12,14,19 The definition of CR varied across proto-
cols, and later trials incorporated the use of functional
imaging in addition to CT imaging. Although the investiga-
tional arm of these trials omitted RT in complete respond-
ers, patients with an incomplete response or PR still
received RT. An example of this paradigm was the CCG
5942 study, in which patients with early favorable, early
unfavorable, and advanced stage HL received risk-based
chemotherapy followed by CT-based response assessment.
Complete responders were randomized between consolida-
tive RT and no further therapy. The results from this group
of studies have been mixed, with some demonstrating that
RT can be safely omitted without compromising progres-
sion-free survival in selected patients,6,9,12-14,18,19 but
others indicated a significant progression-free survival ben-
efit in patients who received consolidative RT.2,6,20 The
interpretation and comparison of results from these trials
are complicated by the different risk groups included,6,17,18
variable definitions of response, and systemic therapies
used.
Adaptive trials using interim response assessment have
included the assignment of rapid early responders (who
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continue to have a CR at the end of chemotherapy) to CMT
or chemotherapy-alone regimens.13,17 In the St. Jude−Stan-
ford−Dana Farber trial, low-risk patients received 2 cycles
of vincristine, doxorubicin, methotrexate, and prednisone
(VAMP) chemotherapy. Patients with a CR by both PET
and CT received 2 additional cycles of VAMP and no RT,
and partial responders received 2 more cycles of VAMP
followed by RT.13 In the AHOD 0031 trial, patients were
treated with 2 cycles of doxorubicin, bleomycin, vincris-
tine, etoposide, prednisone, and cyclophosphamide
(ABVE-PC) chemotherapy followed by a CT-based
response assessment, and responders then received 2 more
cycles of ABVE-PC chemotherapy. After 4 cycles, com-
plete responders by CT and functional imaging were ran-
domized between consolidative RT and no further
therapy.17
Adaptive trials where the chemotherapy regimen was
adjusted based on response to therapy were also applied,
wherein only sites with inadequate or incomplete response
to systemic therapy were irradiated.12,14,16,17 For example,
in the AHOD 0831 study, all patients were evaluated by
PET/CT for response after 2 cycles of ABVE-PC chemo-
therapy. Any sites of disease that had not completely
responded after 2 cycles were considered slow early
responding sites. After completion of chemotherapy, all
sites with either bulky disease at presentation or slow early
response received consolidative RT.16
Which Sites Should Receive Radiation: All
Involved Sites or Only High-Risk Sites (Bulky,
Slow, or Partial Responses)?
RT was historically administered to all sites of disease at
diagnosis in pediatric and adult patients with all stages of
disease. Today, this approach is essentially limited to only
patients with stage I/II disease, as in the AHOD 0431 study,
in which patients with stage IA/IIA disease with <3 sites of
initial involvement with a PR to 3 cycles of doxorubicin,
vincristine, prednisone, and cyclophosphamide received
IFRT to initially involved sites. This approach has been
avoided in contemporary studies of high-risk patients with
stage III/IV disease to limit the use of extensive RT fields
and their subsequent late effects.2,6-9,12,14,17,19,21 In the
POG 9425 study, patients received regional RT fields, such
as the mantle and paraortic fields with or without the pelvis
if disease was within any of these nodal basins. These vol-
umes effectively translated into subtotal lymphoid irradia-
tion (STLI) or total lymphoid irradiation in patients with
stage III/IV disease.8
Alternatively, RT can be selectively administered only
to sites presumed to be at a higher risk of relapse. This may
include sites of bulky disease and sites of either slow
response or PR. The rationale for this approach is that che-
motherapy alone may eradicate nonbulky disease or sites in
rapid early and CR, whereas unfavorable sites may benefit
from treatment intensification, including consolidative RT.
This tailored RT approach can lead to a significant reduc-
tion in the volume of normal tissues irradiated, particularly
in patients with advanced stage disease. Irradiation of only
high-risk sites may improve the therapeutic ratio by mini-
mizing late toxicities through the selective avoidance of RT
in patients with more favorable responses. Table 1 summa-
rizes the inclusion criteria, treatment arms, RT indications,
and accrual status of past and current pediatric HL trials.
Bulky disease is frequently identified as a high-risk fea-
ture and has been irradiated in several trials,15,16 although
no significant difference was observed in patterns of relapse
between bulky and nonbulky sites of disease in the AHOD
0031 study.22 In addition, patients with a PR by CT or PET/
CT after chemotherapy or slow early responders based on
interim PET/CT are also at increased risk of
relapse.12,13,17,18 To improve outcomes, high-risk sites have
also been irradiated.16 For example, the AHOD 1331 study
randomized patients with advanced stage disease between
ABVE-PC and the adcetris, doxorubicin, vincristine, etopo-
side, prednisone, and cyclophosphamide regimen, where
bleomycin was substituted for the anti-CD30 monoclonal
antibody brentuximab vedotin. All patients with bulky and
PET-positive disease (Deauville 4,5) after 2 cycles were to
receive RT to these sites after completion of systemic ther-
apy. In the ongoing S1826 trial, the only sites irradiated are
sites of residual disease after completion of systemic ther-
apy by both PET and CT (>2.5 cm; NCT03907488).
Consensus Statement #1. With advances in systemic ther-
apy, it is clear that not all patients require the same inten-
sity of therapy. Recent adaptive trial designs have treated
patients at highest risk for relapse with targeted RT fields.
The selection of treatment modality and regimen should be
based on curative potential, balanced with the risk of late
effects, to improve survival and quality of life. Limiting the
use of RT to sites with an inadequate response to chemo-
therapy may contribute to a reduction in late effects without
compromising relapse-free survival.
Target Volumes and Principles of Field Design
Recognizing the potential advantages and toxicity costs of
CMT, RT fields decreased in size over time, from total and
STLI to extended-field RT to IFRT. Historically, IFRT
used 2-dimensional planning techniques and bony anatomic
landmarks to develop standardized RT fields that would
completely encompass involved nodal regions. A 2001 sur-
vey of international lymphoma radiation oncology experts,
however, reported large variations in the field borders and
dose prescriptions used between physicians. In response,
Yahalom and Mauch published standardized IFRT guide-
lines to be used in therapeutic trials and clinical practice.23
Modern RT treatment planning now employs 3-dimen-
sional target volumes and organs at risk (OARs) delineated
using CT simulation and based on International
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Table 1 Contemporary pediatric Hodgkin lymphoma clinical trials
Trial
Cooperative
group Inclusion criteria Accrual status Treatment arms/indications for RT
Percentage
treated with RT




Completed All received 4 cycles ABVE-PC
 RER & CR: Randomized to § IFRT
 RER and PR: IFRT
 SER: Randomized to § DECA £ 2
augmented therapy and all received IFRT.
RER: >60% reduction in PPD for all target
lesions.
SER: <60% reduction in PPD for all target
lesions.
CR: >80% reduction in PPD and negative
gallium or FDG-PET scan (less than
mediastinal background blood pool).
67.5%
AHOD 0431 COG Stage IA/IIA (no bulk)
LPHD not allowed.
Closed All received 3 cycles of doxorubicin,
vincristine, prednisone, and
cyclophosphamide.
 If < PR: Off-protocol therapy
 If PR: IFRT
 If CR: Observation (Off-protocol therapy
for high-risk relapse; IV, DECA, and IFRT
for low-risk relapse).
CR: Anatomic reduction ≥80% in PPD and
FDG-PET-negative result.
PR: Anatomic reduction >50% in PPD of
measurable disease regardless of FDG-PET
response.
43.5%
HOD05 SJCRH Stage IB; IIIA; and I-
IIA with any of the
following: Bulky
LMA, E lesions, or
≥3 nodal sites
Closed All receive 12 weeks Stanford V! ERA
(after 8 weeks of chemotherapy)-adapted
RT:
 If CR and nonbulky: 15 Gy in 1.5 Gy/fx
 If PR and/or mediastinal bulk: 25.5 Gy in
1.5 Gy/fx
ERA defined by PET negative and > (CR)
anatomic response or <75% (PR) anatomic
response regardless of PET.
»100%





CXR) and <3 LN
regions and no E
lesion
Closed All receive 8 weeks Stanford V, followed by
ERA-adapted RT:
25.5 Gy in 1.5Gy/fx RT to a site with <75%
anatomic response or PET+, but omitted for
>75% response and PET−.
NR
HLHR13 SJCRH Stage IIB, IIIB, IVA,
or IVB; LPHD not
allowed
Closed ERA driven by metabolic and anatomic
response.
 2 cycles AEPA! ERA! 4 cycles.
CAPDac!§ ERA-adapted RT.
RT given if ERA is Deauville 4-5 or
anatomic response <75% from baseline.
NR
AHOD 0831 COG Stage IIIB-IVB Closed All receive 2 cycles ABVE-PC.
 If CR: 2 cycles ABVE-PC! Risk-adapted
RT.
 If PR/SD: 2 cycles Ifos/Vino! 2 cycles.
ABVE-PC! Risk-adapted RT.
 If PD: Off-protocol therapy.
CR: Deauville 1 or 2
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group Inclusion criteria Accrual status Treatment arms/indications for RT
Percentage
treated with RT
AHOD 1331 COG Stage IIB with Bulk;
IIIB; IVA; IVB
Open Randomized to 5 cycles ABVE-PC versus Bv-
AVEPC! ERA-adapted ISRT.
RER: Deauville 1,2, or 3.
SER: Deauville 4, 5.
CR: Deauville 1,2.
PR: Deauville 3, 4, 5 at the end of treatment.
NR
Euronet-PHL-C1 EuroNet All stages/risk
categories; LPHD
not allowed
All receive 2 cycles OEPA! ERA.
TG1: RT unless CMR on ERA.
TG2: 2 cycles COPDAC versus
COPP! RT unless CMR on ERA.
TG3: 4 cycles COPDAC versus
COPP! RT unless CMR on ERA.
ERA is defined by PET only (§) where
adequate response = no initially involved
PET+ areas remain positive.
33.3%
Euronet-PHL-C2 EuroNet All stages/risk
categories
LPHD not allowed
Open All receive 2 cycles OEPA! ERATL-1:
PET-! 1 cycle COPDac-28 or PET
+! 19.8 Gy RT to initial sites TL-2 and
TL-3: Randomized to 2 (TL2)-4 (TL3)
cycles COPDac-28 versus DECOPDac-21!
LRA (if IR at ERA).
 ERA PET-: No RT.
 ERA PET+, COPDac-28: 19.8 Gy RT to
initial sites §10 Gy boost to LRA PET+
sites.
 ERA PET+, DECOPDac-21, LRA PET−:
Observation.
 ERA PET+, DECOPDac-21, LRA PET
+:28.8 Gy to LRA PET+ sites.
NR
cHOD17 SJCRH All stages/risk
categories; LPHD
not allowed
Open Low and intermediate risk receive 2 cycles
BEABOVP! ERA.
 Low Risk: §ERA-adapted
RT.! Observation.
 Intermediate Risk: 1 cycle BEABOV §
P!§ ERA-adapted RT.
 High-risk: AEPA! ERA! 4 cycles
CADac § P!§ ERA-adapted RT.
ERA driven by metabolic response only RT
given when ERA is Deauville
4 or 5.
NR
Abbreviations: ABVE-PC = doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; AEPA = adcetris, etoposide, predni-
sone, adriamycin; BEABOV§P = bendamustine substitution for mechlorethamine in the original Stanford V backbone with or without prednisone; Bv-
AVEPC = adcetris, doxorubicin, vincristine, etoposide, prednisone, cyclophosphamide; CAPDac, cyclophosphamide, adcetris, dacarbazine;
CMR = complete metabolic response; COG = Children’s Oncology Group; COPDAC = cyclophosphamide, oncovin, prednisone, dacarbazine;
COPP = cyclophosphamide, oncovin, prednisone, procarbazine; CR = complete response; CXR = chest x-ray; DECA = dexamethasone, etoposide, cis-
platin, and cytarabine; DECOPDac = dacarbazine, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone/prednisolone; ERA = early
response assessment; FDG = fluorodeoxyglucose; fx = fraction; Ifos/Vino = ifosfamide, vinorelbine; IFRT = involved-field radiation therapy;
IR = inadequate response; ISRT = involved-site radiation therapy; IV = intravenous; LMA = large mediastinal adenopathy; LN = lymph node;
LPHD = lymphocyte predominant Hodgkin lymphoma; LRA = late response assessment; NR = not yet reported; OEPA = oncovin, etoposide, prednisone,
adriamycin; PD = progressive disease; PET = positron emission tomography; PPD = product of perpendicular diameter of target lesions; PR = partial
response; RER = rapid early responding; RT = radiation therapy; SD = stable disease; SER = slow early responding; SJCRH = St. Jude Children’s
Research Hospital; Stanford V = chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin,
etoposide and prednisone; TG = treatment group; TL = treatment level.
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Commission on Radiation Units and Measurements Reports
62 and 83.24,25 The Euronet PHL-C1 study was one of the
first to define target volumes using gross tumor volume and
clinical target volume (CTV) nomenclature to create
“modified IFRT” fields (NCT00433459). IFRT has now
given way to even more limited target delineation.
Involved-node radiation therapy (INRT), proposed by the
European Organisation for Research and Treatment of Can-
cer (EORTC), delineates the CTV to encompass only lymph
nodes containing macroscopic lymphoma at diagnosis
based on anatomic and functional imaging (CT and PET/
CT) while excluding uninvolved nodes and normal tissues.
INRT requires prechemotherapy CT and PET/CT to be
obtained in the RT treatment position and that coregistra-
tion of this imaging be performed with the CT simulation
for RT treatment planning.26 This is particularly challeng-
ing to achieve in routine clinical practice.
Involved-site RT (ISRT) is conceptually similar to INRT
but permits some uncertainty in interpreting diagnostic imag-
ing for CTV definition. The key difference between ISRT
and INRT lies in the quality and accuracy of prechemother-
apy imaging and the concordance of patient positioning and
image registration to the treatment planning CT. First, ISRT
allows physicians to use their own clinical judgment when
considering potential dose to an adjacent OAR, such that the
CTV can be tailored to spare nearby critical structures such
as the heart.26-28 Second, additional margins are permitted to
allow for uncertainties regarding the anatomic location of
involved nodes in delineating the CTV. In cases where pre-
treatment imaging was not performed in the RT treatment
position, the pretreatment PET was not coregistered with
CT, the CT was performed without intravenous contrast, or
patient positioning, motion, or slice thickness were subopti-
mal, the ISRT CTV may include nodal tissue adjacent to
involved nodes to account for small spatial differences in the
location of initially involved nodes. Although INRT was
originally conceived for treatment of early stage disease,
ISRT is potentially applicable to patients with all stages.
ISRT was applied in the recently completed AHOD 1331
trial, which included only patients with high-risk disease.
ISRT has effectively replaced IFRT in clinical practice, with
most physicians using modern target volume delineation.
Ongoing trials have further reduced target volumes com-
pared with ISRT/INRT to treat only gross residual disease
with small margins based on CT or PET/CT. Historically,
such smaller volumes may have been used as a boost after
treatment of a larger field to lower prescription doses. In the
current St. Jude studies, however, these reduced volumes
are being used for the entire course of RT. Figure 1 depicts
an example of representative target volumes for extended-
field RT, IFRT, ISRT, and gross residual disease alone.
Table 2 describes the target volumes being used in the cur-
rently active or soon-to-be-accruing Children’s Oncology
Group (COG) studies.
Consensus Statement #2: ISRT and INRT are considered
standard of care for HL RT and have replaced extended
fields in contemporary clinical trials. Response-adapted
paradigms are a useful clinical trial construct to help iden-
tify patients who benefit from RT and intensify/de-intensify
therapy based on response. Contemporary trials have
applied RT to all sites of initial disease, bulky and slow
responding sites, or only PET-positive disease after chemo-
therapy. Further study is needed to determine whether ISRT
volumes can be safely reduced to treat smaller volumes,
such as gross residual disease alone. Given that RT vol-
umes may be significantly larger in patients with stage III/
IV disease, different approaches may be needed in patients
with early and advanced stage disease.
Functional Imaging, Simulation, and Treatment
Positioning
Functional imaging using PET in HL is essential for both
accurate staging and high-quality RT treatment planning.29
The addition of PET/CT in pretreatment staging results in dif-
ferent staging in 10% to 30% of patients with HL compared
with contrast-enhanced CT alone by increasing the diagnostic
sensitivity for questionable findings and identifying additional
sites of involvement that were not observed on CT.30,31 Fail-
ure to obtain a PET/CT scan before starting chemotherapy
was associated with a higher risk of relapse in patients with
early stage HL.32 In addition, areas of increased uptake assist
in target volume delineation and can be correlated with out-
comes using midtreatment and postchemotherapy imaging.
The anatomic precision of PET, however, should not be over-
stated. The precise delineation of disease within an enlarged
nodal volume should not necessarily be restricted only to
FDG avid regions. Abnormalities on CT compatible with dis-
ease involvement should be included in the CTV, even in the
absence of increased FDG avidity.27 Oncologists should be
cognizant of potential non-HL sources of FDG uptake in nor-
mal tissues, including brown fat, tonsillar tissues, and normal
thymic uptake, and should seek to distinguish these findings
from disease. The assistance of colleagues in radiology and
other specialties can be critical in this effort.
High-quality prechemotherapy imaging is critical to
delineate appropriate RT target volumes. Given the propen-
sity for neck and thorax involvement in HL, imaging stud-
ies of these regions should always be performed. Contrast-
enhanced CT and PET/CT imaging are strongly advised in
all cases33 unless clear contraindications exist. Pretreatment
PET/CT should ideally be performed in the treatment posi-
tion with the participation of the radiation oncologist. Inad-
equate pretreatment imaging may lead to incorrect over- or
undertreatment of the patient and can potentially lead to
unnecessary irradiation of uninvolved tissues. Because
neck RT is typically performed with a neutrally positioned
or extended neck, it is recommended that lymphoma
patients with PET/CT imaging have their neck similarly
positioned to improve image fusion. Similarly, if the axilla
is not involved, it would be beneficial to have the patient
undergo PET/CT imaging with the arms at their sides to
assist in image fusion (Fig. 2).
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Table 2 Radiation therapy fields, target volumes and administration on contemporary clinical trials
Target volumes
Trial Field design GTV CTV Modality allowed
4-dimensional
CT used Dose
AHOD 0031 IFRT Any lymph node measuring
>1.5 cm in a single axis on CT
Anatomic compartment defined in
the protocol for IFRT based on
sites of initial involvement
AP/PA (except certain
sites; eg, inguinal nodes)
No 21 Gy/14 fx
AHOD 0431 IFRT Any lymph node measuring
>1.5 cm in a single axis defined on
CT
Anatomic compartment defined in
the protocol for IFRT based on
sites of initial involvement
AP/PA (except certain
sites; eg, inguinal nodes)
IMRT not allowed
No 21 Gy/14 fx
HOD05 Tailored-field Initially involved nodal site -GTV +2 cm margin with additional
margin to account for patient and
beam effects, respecting pushing
borders and anatomic barriers to
disease spread
-Patients with mixed response will
have treatment fields modified to
limit the volume treated after 15
Gy to only sites with <CR with a
2 cm margin and bulky LMA,
regardless of response
AP/PA; 3-dimensional






No CR: 15 Gy/10 fx
PR or bulky LMA:
25.5 Gy/17 fx





HLHR13 ISRT Postchemotherapy lymph nodes in
PR









cHOD17 Modified ISRT Postchemotherapy lymph nodes in
PR
GTV + 0.5 cm (anatomically
constrained)
IMPT Yes Deauville 1-3: None
Deauville 4-5:
25.5 Gy/17 fx
AHOD 0831 Modified IFRT*
1. Initial bulk, postchemotherapy
residual
2. Macronodular splenic disease,
entire spleen is considered GTV
3. Postchemotherapy residual non-
bulky disease with PET2 SER
4. Postchemotherapy residual non-
bulky disease measuring ≥2.5 cm
in axial diameter at completion of
chemotherapy in patients with
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Trial Field design GTV CTV Modality allowed
4-dimensional
CT used Dose
AHOD 1331 ISRT GTV: Imaging abnormalities
persistent after all chemotherapy
that conform to prechemotherapy
nodal and non-nodal tissues
involved before treatment that
meet the criteria for requiring RT
(LMA or SRL)
GTV-PET+: area of imaging
abnormality that remains PET5+
(Deauville ≥3)
Initially involved lymph nodes/
tissues, accounting for response to
chemotherapy.
 Typically, entire nodal fossa/
level that contained initially
abnormal node(s) will be con-
toured as CTV. In general, mar-
gin of 1.5 cm above/below
involving nodes is recommended
AP/PA; IMRT; proton Yes 21 Gy/14 fx
If PR with persistent
PET5+ disease, small
volume boost of
9 Gy/6 fx added
Euronet-PHL-C1 Modified IFRT PTV1: All initially involved lymph node before chemotherapy + safety
margin of 1-2 cm taking into account the area of involvement
PTV2: Includes all lymph nodes with poor response after 2 cycles of
chemotherapy with a 1-2 cm safety margin
3-dimensional conformal
RT
Yes PTV1: 19.8 Gy/11 fx
PTV2: 10.8/6 fx
Euronet-PHL-C2 ISRT/ INRT Standard arm: LRA PET+ node(s) >
1 cm (GTV boost).
Experimental arm: LRA PET+




GTV + 5 mm, boost if required to
postchemotherapy GTV + 5 mm;
ERA PET+ EN sites (eg, bone,
liver, lung) + 5-30 mm depending
on site
Experimental arm: Nodal GTV + 5
mm; EN sites (eg, bone, liver,






at discretion of treating
oncologist.
No Standard arm:




Abbreviations: AP/PA = anteroposterior/posteroanterior; CR = complete response; CT = computed tomography; CTV = clinical target volume; EN = extranodal; fx = fraction; GTV = gross tumor volume;
IFRT = involved-field radiation therapy; IMPT = intensity modulated proton therapy; IMRT = intensity modulated radiation therapy; ISRT = involved-site radiation therapy; LMA = large mediastinal adenop-
athy; PET = positron emission tomography; PET2 = Deauville score on interim PET/CT after 2 cycles of chemotherapy; PET5 = Deauville score on PET/CT after 5 cycles of chemotherapy; PPD = product of
perpendicular diameter of target lesions; PR = partial response; PTV = planning target volume; RT = radiation therapy; SER = slow early responding; SRL = slow-responding lesion.
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In addition to pretreatment imaging, simulation also com-
prises an important and sometimes underemphasized ele-
ment in the delivery of high-conformal RT. Patient
positioning should be individualized to ensure reproducibil-
ity, enable accurate delineation of target volumes, and
provide clinicians with the best avenue to minimize dose to
OARs. The use of intravenous contrast is recommended
when practical to aid in the delineation of target volumes
and certain OARs, such as the left anterior descending
artery. For patients treated to the cervical neck, comfortable
Fig. 1. Representative field borders/dose distribution for a representative patient with Hodgkin lymphoma and mediastinal
involvement (delineated in the center with pink contours) receiving treatment with Mantle field, involved-field and involved-
site radiation therapy (yellow) and to residual disease (blue) alone after chemotherapy. The heart (red) and female breast
(pink) are also illustrated.
Fig. 2. Computed tomography (CT) simulation fusion with CT component from baseline positron emission tomography/CT
scan where patient simulation setup is different from staging scan (arms up vs down), illustrating the difficulty with target vol-
ume delineation in the axilla, supraclavicular, and cervical regions.
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chin extension and use of mask immobilization may help to
reduce oral cavity and salivary gland dose and minimize
planning target volume expansions. Patients with mediasti-
nal disease and either no or limited neck disease who will
receive intensity modulated radiation therapy (IMRT) may
benefit from positioning the arms overhead to minimize col-
lateral radiation to the arms. Comfortable and reproducible
positioning may be improved using customized VacLok
devices over a wing board. Patients with axillary disease
may be treated with either arms up or akimbo positioning.
Akimbo positioning may be more comfortable, particularly
in older patients, and may be more reproducible for cases
treated with proton therapy (PT). This position, however,
may be less favorable in patients treated with rotational
gantries using IMRT or PT due to collision concerns. Ulti-
mately, simulation should emphasize patient comfort and
setup reproducibility and be individualized. The right
answer in each clinical case may vary between centers.
Consensus Statement #3: Functional imaging is a cen-
tral pillar of contemporary HL therapy in developed coun-
tries, and clinicians are strongly encouraged to obtain
pretreatment, interim, and posttreatment imaging to ade-
quately assess response. Where there is no routine access
to PET/CT, caution should be taken when applying the
results of PET-directed therapy trials in clinical practice.
Radiation Therapy Techniques and Modalities
The RT techniques and modalities allowed in recent HL
clinical trials are reported in Table 2. Historical trials
used 2-dimensional planning and anatomic-based fields
to cover targeted nodal volumes based on bony anat-
omy. CT-based 3-dimensional volumetric planning is
now the standard of care, and more advanced techni-
ques, including IMRT and PT, are increasingly used.
The use of IMRT is permitted in AHOD 0831 and
EORTC H11, and both PT and IMRT are allowed on
AHOD 1331, HLHR13, and EuroNet-PHL-C2.
Three-dimensional conformal RT (CRT) enables greater
dose deposition in the target and reduces the dose to non-
target normal tissues by improving the precision of target
volume delineation and enabling the evaluation of target
coverage and OAR sparing with a dose-volume histogram.
In most cases, 3-dimensional CRT is typically administered
with parallel opposed anteroposterior/posteroanterior fields,
leaving portions of OARs that are in field to receive the pre-
scription dose. IMRT and volumetric modulated arc therapy
enable greater sparing of OARs adjacent to the target vol-
ume from receiving higher doses at the expense of increas-
ing the normal tissue volumes receiving low-to-
intermediate doses. This low-dose bath is of concern
because it may increase the risk of radiation-induced sec-
ondary malignant neoplasms (SMNs). The magnitude of
risk posed by this low-dose exposure remains uncertain
until mature follow-up data become available.34,35 Table 3
is adapted from Tseng et al and summarizes the RT dose-
response relationships for different toxicities observed in
survivors of HL for SMNs, cardiovascular, pulmonary, and
endocrine late effects.36
PT eliminates RT dose deposition beyond the target due
to its unique dose distribution pattern, known as the Bragg
peak. As a result, PT can deliver highly conformal doses to
the CTV, as with IMRT, while providing greater sparing of
normal tissues and reducing the total integral dose delivered
to the patient. In a review of 14 published studies compar-
ing 3-dimensional CRT, IMRT/volumetric modulated arc
therapy and PT dosimetry for patients with lymphoma,
IMRT was found to reduce the RT dose to the heart and
esophagus at the expense of higher thyroid and breast doses
compared with 3-dimensional CRT. PT significantly
reduced the dose to the heart, thyroid, breast, lung, esopha-
gus, and total body compared with both 3-dimensional
CRT and IMRT.36 The benefit from OAR sparing is great-
est in patients with long anticipated survival, because the
risk of radiation-induced cardiovascular disease, SMNs,
and other effects increases over time. As a result, patients
with HL who are younger or have a significant reduction in
dose to nearby OARs are expected to have the greatest
potential benefit from PT.
Patients with disease extending into the inferior medias-
tinum may also comprise a subgroup that derives a greater
potential benefit from PT due to a greater reduction in heart
dose.37-40 PT may improve sparing of many OARs, but the
delivery can be quite challenging due to setup uncertainties
and changes in external anatomy and tissues within the
chest. Due to the complexity of PT treatment, COG requires
institutions to demonstrate accuracy and proficiency of
delivery using the Imaging and Radiation Oncology Core
thoracic phantom before patients are permitted to receive
PT on clinical trials.
To date, outcomes and follow-up for patients treated
with either IMRT or PT remain too short to demonstrate a
significant reduction in late toxicities compared with 2- and
3-dimensional CRT. The absence of data demonstrating
that these dosimetric benefits translate into a clinical benefit
is not unexpected because many serious adverse effects
occur 10 years or longer after completion of therapy.41
Favorable event-free survival, however, has been reported
in several retrospective studies in adult and pediatric
patients with HL.42-46 To date, grade 3 pneumonitis was
rare after IMRT and PT.42,43,47,48 Long-term follow-up of
toxicity is needed from these advanced photon and PT data
sets. In addition, toxicity will be significantly affected by
target site, technique, and target volume delineation param-
eters, which need to be accounted for in the interpretation
of these data.
Motion Management
Four-dimensional CT is recommended for thoracic and
abdominal primary tumor sites where target volume and/or
normal organs move with respiration. Respiratory motion
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Table 3 Summary of literature describing risk of secondary cancers, cardiovascular disease, pulmonary toxicity, and endocrinopathies among Hodgkin lymphoma survivors treated with
radiation













General population RT alone: SMR 5.4 (3.4-8.2)
RT and CT: SMR 4.4 (2.0-8.3)
Salvage Rx: SMR 8.3 (6.1-11.2)
Castellino et al.,
201156
USA (CCSS patients with HL)
N = 2742





No RT <30 Gy*: HR 1.9 (0.4-8.7)




















(105 cases and 266 controls)




0-3.9 Gyy 4.0-6.9 Gy: RR 1.8 (0-4.5)
7.0-23.1 Gy: RR 4.1 (1.4-12.3)
23.2-27.9 Gy: RR 2.0 (0.7-5.9)
28.0-37.1 Gy: RR 6.8 (2.3-22.3)
37.2-40.4 Gy: RR 4.0 (1.3-13.4)
40.5-61.3 Gy: RR 8.0 (2.6-26.4)
[≥4 Gy: RR 3.2 (1.4-8.2)]








(227 cases and 455 controls)




<5 Gyy >0-4.9: Gy: RR 1.3 (0.3-4.9)
5.0-14.9: Gy: RR 4.1 (0.7-22)
15.0-29.9 Gy: RR 2.5 (0.1-16.1)
30.0-39.9 Gy: RR 8.6 (2.9-30)
≥40 Gy: RR 7.2 (2.2-28)
[≥5 Gy: RR 5.9 (2.7-13.5)]












<30 Gy and no RTy ≥30 Gy: RR 4.3 (1.5-15.3) ERR/Gy = 0.38 (0.04-






(89 cases and 91 controls)




0 Gyy 0.1-0.9 Gy: RR 1.3 (0.4-4.1)
1.0-4.9 Gy: RR 1.0 (0.3-3.5)
5.0-24.9 Gy: RR 0.5 (0.1-2.7)
25.0-34.9 Gy: RR 4.6 (1.2-20.5)
35.0-39.9 Gy: RR 8.2 (2.6-29.7)
≥40 Gy RR: 4.2 (1.2-15.6)
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Table 3 (Continued)








(36 cases and 70 controls)












N = 2232 (88 deaths)
Average 29 y (2-82)
Treated 1960-1990
Cardiac death General population 0-30 Gy*: SMR 2.6 (0.4-8.7)




N = 1261 (45 deaths)




General population RT alone: SMR 7.2 (4.2-11.6)
RT and CT: SMR 5.5 (2.2-11.3)









No RT >0-29 Gy*: HR 2.3 (1.3-3.8)
30-35 Gy*: HR 3.1 (2.3-4.2)
≥36 Gy*: HR 3.8 (3.0-5.0)
Patients treated with







(325 cases and 1204 controls)





No RT >0-5 Gyy: RR 1.14 (0.62-2.10)
5-14 Gy: RR 2.14 (1.28-3.58)
15-19 Gy: RR 2.76 (2.10-3.59)
20-24 Gy: RR 2.79 (2.23-3.49)
25-34 Gy: RR 3.21 (2.52-4.09)
35-45 Gy: RR 2.54 (0.96-6.69)
ERR/Gy 0.074 (0.033-












No RT ≤30 Gyy: RR 1.4 (0.5-3.8)
31-35 Gy: RR 3.1 (1.7-5.6)
36-40 Gy: RR 5.4 (3.9-7.7)
>40 Gy: RR 11.8 (4.9-28.5)





(91 cases and 278 controls)





No RT 1-15 Gyy: RR 1.27 (0.86-1.89)
16-20 Gy: RR 1.65 (0.98-2.77)
21-25 Gy: RR 3.84 (1.97-7.47)
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Table 3 (Continued)

















No RT RT to neck/mediastinum: HR 2.5
(1.1-5.6)
Pulmonary toxicity
Ng et al., 200876 United States (DFCI/BWH)
N = 52
Median 31 y (18-69)
Treated 2001-2005
Decline in %DLCO N/A MLD ≥13 Gy or V20 ≥ 33% = 60%
persistently declined %DLCO
ERR/Gy −0.96 (−1.79 to









Diabetes General population ≥36 Gy paraortic/spleen HR 2.3
(1.54-3.44)
≥36 Gy paraortic alone HR 1.82
(1.02-3.25)
HR/Gy mean dose to





N = 53 (22 cases)
Median age 28 y (14-70)
Treated 2001-2009
Hypothyroidism N/A Cumulative risk (median follow-up:
32 mo): V30 to thyroid gland ≤
62.5% = 11.5% hypothyroidism
V30 to thyroid gland >
62.5% = 70.8% hypothyroidism
Abbreviations:%DLCO = percentage predicted carbon monoxide-diffusing capacity; AER = absolute excess risk; CCSS = Childhood Cancer Survivor Study; CT = chemotherapy; DFCI/BWH = Dana-Farber
Cancer Institute, Brigham and Women’s Hospital; ERR = excess relative risk; HL = Hodgkin lymphoma; HR = hazard ratio; MLD = mean lung dose; N/A = not available; RR = relative risk; RT = radiation ther-
apy; Rx = prescription; SIR = standardized incidence ratio; SMR = standardized mortality ratio.
* Prescribed dose.
y Estimated dose to where late outcome occurred.
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management is advised to ensure appropriate coverage
when target volumes move with breathing. Motion manage-
ment strategies include the use of an internal target volume
to account for tumor excursion during all phases of the
breathing cycle, abdominal compression, or gated delivery.
Regardless of the strategy used, we recommend including
the entire lungs in the treatment planning CT for all chest
wall and thoracic tumors to enable accurate pulmonary
dose measurements.
Deep-inspiration breath hold (DIBH) is an important
technique in modern RT planning and delivery and has
been reported in pediatric patients.49 In general, this tech-
nique results in reduced lung dose compared with free-
breathing delivery and may shift the heart inferiorly,
which can potentially reduce the heart dose in selected
patients receiving RT to the mediastinum. Reports from
Petersen et al and Charpentier et al both demonstrated that
DIBH was associated with lower mean heart doses, heart
V20, and lung V20 in patients treated with both 3-dimen-
sional CRT and IMRT.50,51 DIBH also conferred lower
estimated lifetime excess risks of cardiovascular disease
and secondary lung, breast, and thyroid cancers.52
Although 4-dimensional CT and DIBH are increasingly
incorporated into clinical practice, few outcomes have
been reported. DIBH may be particularly helpful in
patients with superior mediastinal disease by increasing
the separation between the heart and the inferior extent of
disease. The magnitude of benefit may be less in patients
with lower mediastinal disease if the CTV moves in con-
cert with the heart. In all clinical scenarios, the volume of
the irradiated lung is typically reduced with DIBH. Lym-
phoma radiation oncologists are strongly encouraged to
consider DIBH in appropriate patients where OAR dosing
may be improved with this technique.
Consensus Statement #4: Pre- and posttreatment imag-
ing (where appropriate) should be fused to the RT treatment
planning study to aid in target volume delineation. The
selection of CT simulation positioning, immobilization devi-
ces, motion management, and treatment modality are all
essential to optimizing the efficacy of RT, improving confor-
mality, and minimizing dose to OARs. Lymphoma radiation
oncologists should leverage advanced RT technologies and
motion management strategies where appropriate, includ-
ing DIBH.
Patterns of Failure and Radiation Therapy Dose
Based on the experience derived from decades of clinical
trials, the standard consolidative RT dose for patients with
primary disease after induction chemotherapy is 20 to 30
Gy in adults and 20 to 25.5 Gy in children.17,53 These doses
are based on clinical trials where most patients were irradi-
ated and the predominant site of failure was within the RT
field. On 2 prospective clinical trials in the St. Jude Child-
ren's Research Hospital consortium from 1990 to 2000, of
195 pediatric patients treated with either VAMP or VAMP/
cyclophosphamide, vincristine, and prednisone (COP) fol-
lowed by IFRT to 15 to 25.5 Gy, 27 patients relapsed and
81% recurred in field.54 In AHOD 0031, 244 patients
(14.3%) relapsed, and 94% of recurrences had some com-
ponent of in-field failure after 21 Gy.22 In contrast, in adult
patients with stage I to II and bulky mediastinal disease
who received 36 Gy (n = 264) on the Intergroup E2496 trial,
in-field relapses represented 61% of all relapses after doxo-
rubicin hydrochloride, bleomycin sulfate, vinblastine sul-
fate, and dacarbazine (ABVD) and 52% of all relapses after
mechlorethamine, doxorubicin hydrochloride, vinblastine,
vincristine, bleomycin, etoposide, and prednisone (Stanford
V).55 Although relapse patterns are also affected by sys-
temic therapy intensity, these studies suggest that doses of
15 to 25.5 Gy lead to higher rates of in-field relapse com-
pared with doses akin to 36 Gy.
Although newer trials are identifying patients with
favorable outcomes for whom RT may be eliminated, these
adaptive trials are also identifying patients at a higher risk
of relapse. Such patients may benefit from higher-than-stan-
dard RT doses. In AHOD 1331 and Euronet-PHL-1 and 2,
pediatric patients with residual FDG-avid disease receive
doses of 30 Gy rather than 20 to 21 Gy (Table 4). In
EORTC H11, adult patients with FDG-avid disease after
chemotherapy receive 36 Gy rather than 30 Gy.
Consensus Statement #5: The optimal RT dose intensity
as part of CMT is dependent on disease stage/risk status,
the chemotherapy regimen, and response to therapy. His-
torically, pediatric and adult patients received doses of
approximately 20 and 30 to 36 Gy, respectively. Selection
of RT dose outside of clinical trials should be consistent
with both the selected treatment paradigm and response
assessment. Future pediatric trials that focus on reducing
the number of patients receiving RT should consider the use
of higher doses, such as 30 Gy in selected higher-risk
patients. Patients with incomplete response after chemo-
therapy may benefit from treatment intensification, includ-
ing but not limited to a higher dose RT of >30 Gy to
selected sites.
Normal Tissue Toxicity
Although cure rates for HL generally exceed 85%, long-
term survivors are at high risk of developing late adverse
effects due to their chemotherapy and RT.41 Castellino et al
reported that 5-year survivors of pediatric HL in the Child-
hood Cancer Survivors Study (CCSS) diagnosed between
1970 and 1986 had a substantial excess absolute risk (EAR)
of morbidity and mortality compared with the general popu-
lation, including an EAR of 23.9 for SMNs and 13.1 for car-
diovascular disease per 10,000 person-years. The SMNs
with the greatest EAR compared with the general popula-
tion were for hematopoietic (6.8), sarcoma (5.6), breast
(4.4), and gastrointestinal (4.4) malignancies per 10,000
person-years. The 30-year cumulative incidence of grade 3
+ cardiovascular and pulmonary complications were 11.1%
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Table 4 Treatment outcomes




In-field Out of field Both
7.6 y HOD90/HOD94
Pediatric54
195 VAMP; VAMP/CVP IFRT (15-25.5 Gy) 27 (13.8) 14 (51.9) 5 (18.5) 8 (29.6)
6.5 y Intergroup E2496
Adult55
135 ABVD £ 6-8 IFRT (36 Gy) 19 (14.1) 8 (42.1) 8 (42.1) 3 (15.8)
129 Stanford V £ 12 weeks IFRT (36 Gy) 23 (17.8) 7 (30.4) 11 (47.8) 5 (21.7)
4 y AHOD 0031
Pediatric22
1712 ABVE-PC £ 4 (RER, CR) IFRT (21 Gy) 32 (9.0) 15 (47) 4 (13) 13 (41)
ABVE-PC £ 4 (RER, CR) None 51 (14.1) NS NS NS
ABVE-PC £ 4 (RER, <CR) IFRT (21 Gy) 59 (10.3) 24 (41) 11 (19) 24 (41)
ABVE-PC £ 2, ABVE-
PC £ 2 §DECA (SER)
IFRT (21 Gy) 52 (17.1) 27 (52) 2 (4) 23 (44)
Uncategorized Uncategorized 4 (8.7) 2 (50) 0 (0) 2 (50)
4.2 y NCIC/ECOG
Adult (>16 y)79
203 §ABVD £ 2 SNRT (35 Gy) 10 (4.9) 3 (30) 3 (30) 4 (40)
196 ABVD £ 6-8 None 23 (11.7) 20 (87) 0 (0) 3 (13)
4.4 y Hopkins Pediatric/
young adult (≤40 y)80
37 ABVD (adult) IFRT (<30 Gy) 7 (18.9) 3 (43) 1 (14) 3 (43)
37 ABVE-PC (pediatric) IFRT (≥30 Gy) 6 (16.2) 1 (17) 5 (83) 0 (0)
Abbreviations: ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVE-PC = doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; CR = complete response;
CVP = cyclophosphamide, vincristine, and procarbazine; DECA = dexamethasone, etoposide, cytarabine, and cisplatin; ECOG = Eastern Cooperative Oncology Group; IFRT = involved-field radiation therapy;
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(95% confidence interval, 8.5%-13.8%) and 5.1% (95%
confidence interval, 3.3%-6.9%), respectively.56
The CCSS is a great resource for identifying factors
associated with late toxicity from the treatment of pediatric
patients. Most patients with HL in the CCSS were treated
with outdated treatment fields and doses (eg, STLI to doses
of 40 Gy), which makes it difficult to extrapolate their out-
comes to modern radiation field designs, techniques, and
doses. Zhou et al compared the normal tissue dose received
by 50 patients with HL in the CCSS who were diagnosed
between 1970 and 1986 with 191 patients treated on
AHOD0031 and AHOD0831 who were diagnosed between
2002 and 2012. In the more contemporary patients with HL
treated on COG studies, mean heart dose decreased by 22.9
Gy (68.6%) and 17.6 Gy (56.8%) in patients with early and
advanced stage disease, respectively. Similarly, mean
breast dose also decreased by 15.5 Gy (83.5%) and 11.6 Gy
(70%) in patients with early and advanced stage disease,
respectively. Significant reductions in lung and thyroid
dose were also observed in COG patients compared with
CCSS participants. Reductions in the total prescribed RT
dose and changes in field volumes served as major contribu-
tors to the observed differences.57 This suggests that
patients treated with RT in the present day receive signifi-
cantly lower doses to the heart, lungs, breast, and thyroid
and are therefore unlikely to develop the same degree of
treatment-related late toxicities compared with CCSS
patients.
Table 3 summarizes published manuscripts reporting on
risk factors for SMNs, cardiovascular morbidity, and other
late effects as a function of RT dose.36 Importantly, many
of the published outcomes were derived from the now anti-
quated extended-field RT and STLI fields. Patients treated
to these fields often received RT to the stomach and pan-
creas to high doses, leading to significantly increased risk
of diabetes and SMNs of the pancreas and stomach. In addi-
tion, the RT doses delivered to the heart significantly
increased the risk of valvular disease, congestive heart fail-
ure, and early cardiac death. Treatment with modern ISRT
fields to 30 Gy using IMRT or PT is expected to substan-
tially reduce these risks.58,59
Consensus Statement #6: Athough there is insufficient
long-term follow-up data to demonstrate reductions in late
effects from IMRT and PT in HL, robust outcomes data
have demonstrated that dose responses exist for cardiovas-
cular disease/death, lung and thyroid dysfunction, SMNs,
and numerous other late effects across multiple disease
sites. Late effects are the leading causes of death in HL sur-
vivors, and lymphoma radiation oncologists should pursue
all strategies to reduce late morbidity and mortality
through a reduction in RT use where appropriate, minimiz-
ing radiation to high-risk tissues, and use of advanced RT
modalities and novel technologies. Strategies to prospec-
tively collect patient outcomes, dosimetry, and late effects
and quantify the impact of modern RT on HL morbidity and
survival should be pursued within cooperative groups and
compared across trials.
Conclusions
RT remains an integral component in the management of
many patients with HL, and the decision to use CMT should
rest on appropriate patient selection and consideration of
clinical benefits relative to toxicities.60 Based on results
from several trials published within the last 7 years, better
identification of patients who will benefit from RT has led
to an increasing number of patients who may defer RT and
its potential effects. Modern RT fields, modalities, and
delivery techniques have substantially reduced RT exposure
to uninvolved normal tissues, which is expected to further
reduce late toxicities from RT. We encourage HL investiga-
tors to continue to provide sophisticated guidance on RT
delivery in future clinical trials to ensure the most appropri-
ate and effective use of RT.
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